Tune in for the latest news and trends in this month’s episode of the Scope of Things, where host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves’ disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA’s new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more. Joining the discussion is Aaron Mackey, vice president of AI and data science at Lokavant, who talks about the unintended consequences of decisions made during trial planning that can lead to questionable conclusions, how AI and ML are helping with the diversity issue in trial participation, and his stop gap emergency plan to keep trials on track if there is no digital support available. SHOW NOTES News Roundup Phase 3 trial for Graves’ disease Article in Clinical Research News  Quality of life measures in cancer studies Study in Journal of Clinical Oncology Article in Clinical Research News Rapid recruitment for a diagnostic tampon trial Article in Clinical Research News Reference trial emulation Study in PLOS Medicine  Walgreens/BARDA partnership News brief in Clinical Research News “Detective” algorithm for improving trial design Study in Nature Genetics Exclusion of people with Duffy-null phenotype Study in JAMA Network Open    The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.

Ver todos los episodios